

Conference Paper

# Experimental Models Point Mutations In *Plasmodium falciparum* *pfatpase6* Gene Exposed to Recuring Artemisinin *In Vitro*

Lilik Maslachah<sup>1</sup>, Yoes Prijatna Dachlan<sup>2</sup>, Chairul A.Nidom<sup>3</sup>, and Loeki Enggar Fitri<sup>4</sup>

<sup>1</sup>Laboratory of Veterinary Pharmacy, Faculty of Veterinary Medicine, Universitas Airlangga

<sup>2</sup>Department Parasitology, Faculty of Medicine, Universitas Airlangga

<sup>3</sup>Laboratory of Biochemystri, Department of Basic Medicine, Faculty of Veterinary Medicine, Universitas Airlangga

<sup>4</sup>Department of Parasitology, Faculty of Medicine, Brawidjaya University

## Abstract

The aims of this research to prove that repeated exposure of artemisinin can cause *pfatpase6* gene mutation on *Plasmodium falciparum* in vitro. The research methods used culture In Vitro *Plasmodium falciparum* of strain 2300 IC<sub>50</sub> value determination test artemisinin, artemisinin repeated exposure test (PO<sub>1</sub>, PO<sub>2</sub>, PO<sub>3</sub> dan PO<sub>4</sub>) dose IC<sub>50</sub>, DNA extraction, gene amplification of *pfatpase6* using Polymerase Chain Reaction (PCR) technique, electrophoresis, PCR product purification, labeling DNA from PCR results, DNA precipitation of PCR product, application of product labeling on the sequencing machines, analysis of the results of sequencing, and Data Analysis. The results of PCR *pfatpase6* gene amplification include region 6 – 3216 for codon 89-1031 located in exon 1 and 2 *Plasmodium falciparum* 2300 by using five pairs of primers. Primer pair 1FR produce a long amplicon of 737 bp which covers of codon 89; primer pair 2FR produce a long amplicon of 813 bp which covers of codon 263, 431; primer pair 4FR produce a long amplicon of 700 bp which covers of codon 460, 465, 623; primer pair 5FR produce a long amplicon of 550 bp which includes of codon 683, 769; and primer pair 6FR produce a long amplicon of 876 bp which covers of codon 898, 1031. Multialignment *pfatpase6* gene *Plasmodium falciparum* of strains Papua 2300 point mutations are obtained in the form of transition and transversion in treatment groups at the same nucleotide region 123, 2035, 2043, 2138 dan 2148. Conclusion of this research Artemisinin repeated exposure can cause point mutations in *pfatpase6* genes *Plasmodium falciparum* of strains 2300 in vitro.

**Keywords:** Artemisinin, *Plasmodium falciparum* of strain Papua 2300, *pfatpase6* gene, point mutation.

Corresponding Author:

Loeki Enggar Fitri

Received: 03 October 2017

Accepted: 10 October 2017

Published: 29 November 2017

Publishing services provided by Knowledge E

© Lilik Maslachah et al. This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Selection and Peer-review under the responsibility of the VMIC Conference Committee.

## OPEN ACCESS

## 1. Introduction

Development of *Plasmodium falciparum* resistance to antimalaria drugs and decreased efficacy of artemisinin and its derivatives cause malaria treatment to become increasingly difficult [1]. This has become one of the foremost health problems in the world because there is no new drug to substitute for artemisinin. Prevention of artemisinin resistance should be a top priority throughout the world. *Plasmodium falciparum* resistance to artemisinin can happen because it is influenced by a number of factors, viz. evolution of parasites to survive drug administration and environmental changes, such as nutrient limitation, toxic compounds and temperature that impose new selective and trigger selection of adaptive genetic variants [2, 3]. In the former situation, there is a change in parasite's lifecycle through retardation of growth at the early ring stage and mutations in certain genes [4–6].

For instance, resistance to artemisinin has been attributed to mutations in *Plasmodium Falciparum* adenine triphosphatase 6 gene (*pfatpase6*) [4, 7]. Variant Pfatpase6, e.g. L263E, E431K, A623E and S769N, have been linked to an increased 50% inhibitory concentrations ( $IC_{50}$ s) of artemether against *Plasmodium falciparum* growth in culture [8]. Pfatpase6 variant I89T was found in isolates from Thailand [9]. Variant H243Y from Central Africa and silent T2694A mutation from SaoTome and Principe [10]. Thirty-three single nucleotide polymorphisms (SNPs) also were found in 39%, 29% and 7% of *P. falciparum* isolates from East and West Africa resulting in *pfatpase6* mutations E431K, N569K and A630S [11]. In Iran all *Plasmodium falciparum* isolates exposed artemisinin (ACT) as first line antimalarial therapy for four years contained mutations L263E and A623E whereas 23% of those not exposed to the drug contained E431K mutation in Sistan and Baluchistan province, so reported that 2.6% of *Plasmodium falciparum* isolates are resistant to artesunate and all contain *pfatpase6* S769N mutation [12].

Although the mechanism of *falciparum* resistance to artemisinin remains under investigation Most important molecular surveillance of artemisinin resistance based on multi genetic markers could be more informative than relying on any one particular molecular marker [13]. it is believed that the artemisinin resistance occurs because of mutations in *pfcr*, *pfmdr1*, *pfatpase6* and *pfk13* [14, 15].

The occurrence of resistance due to exposure to artemisinin has not to date been investigated in *P.falciparum* isolates of Indonesian origin. In this study, we investigated the effects of artemisinin exposure to Indonesian chloroquine-resistant *Plasmodium falciparum* strain 2300. The results of this research can be used as the basis for the

development of malaria therapies through molecular approaches and development of artemisinin modification by molecular modeling.

## 2. Materials and Methods

### 2.1. Materials

*Plasmodium falciparum* strain 2300 (chloroquine-resistant) was from Ministry of Health (LITBANGKES) Indonesia and artemisinin from Sigma. parasite DNA extracted using Invitro gen Kit, five pairs of primer, Purification, precipitation of PCR product and labelling as using Qiagen Kit, *In vitro* cultivation of *Plasmodium falciparum*

*Plasmodium falciparum* strain 2300 was grown in culture using the method of Trager and Jensen (1976) [16]. The parasites were synchronized at ring stage with 5% sorbitol treatment that selectively kill all late parasite stages. Culture were followed by standard conditions for 48 h [17]. Parasite growth was monitored by measuring parasitemia of Giemsa-stained thin blood smears after 48 hours until proportion 5% of ring growth [18, 19]. IC<sub>50</sub> value (concentration required to inhibit growth by 50%) of artemisinin against *Plasmodium.falciparum* strain 2300 growth in culture was determined by adding 10<sup>-3</sup>, 10<sup>-4</sup>, 10<sup>-5</sup>, 10<sup>-6</sup>, 10<sup>-7</sup>, 10<sup>-8</sup>, 10<sup>-9</sup>, 10<sup>-10</sup> M artemisinin to parasite cultures at ring stage and monitoring parasitemia as described. Experiments were conducted in duplicate in a 24-well microplate.

### 2.2. Exposure to artemisinin

For each treatment, 0.5 µl RBC (hematocrit 15%) plus 1µl of infected RBC (>5% parasitemia) were added to 1350 µl of culture medium containing 150 µl artemisinin corresponding to IC<sub>50</sub> concentration. Control sample did not contain the drug. Parasite suspensions were cultured as described above for 48 hours, washed twice with complete medium and cultured as before. First artemisinin exposure (PO1) using IC<sub>50</sub> values (10<sup>-8</sup> M). If parasite viable and reaches 5% parasitemia IC<sub>50</sub> assesment as before. Further results newly IC<sub>50</sub> used for the second artemisinin exposure (PO2) so the same way to third and fourth artemisinin exposure (PO3, PO4) [2, 20].

TABLE 1: Primers Used in The Study for Amplification of Selected Regions of *Pfatpase6*.


Primer	Nucleotide Primer Sequence
S1F	F: CTTATTATATCTTTGTCATTCTG
S1R	R: CCACATACAATAGCGGTAGATG
S2F	F: AATAAACTCCCGCTGATGC
S2R	R: TTCTCCATCATCCGTTAAAGC
S4F	F: AAGATGAAGGAAATGTTGAAGC
S4R	R: CCCAATTTGAGTGAAACAA
S5F	F: GGAACAACAAATGGATATGA
S5R	R: TCCTTTTCATCATCTCTTCA
S6F	F: GAGCATTAAGAACACTTAGCTTTGC
S6R	R: CTGTTGCTGGTAATCCGTCA

### 2.3. PCR amplification and sequencing of *pfatpase6*

Parasite DNA was isolated using a commercial kit (Invitrogen). Primers employed in PCR amplification of sequences containing codons suspected of frequent mutations associated with artemisinin resistance are listed in Table 1 (Imwong *et al.* (2010) [21]).

PCR was carried out in a 20 µl mixture containing primers 1µl (F) 1µl (R), 2 µl DNA template, 10 µl 2xPCR master mix solution. Thermocycling was performed in a Bioer PCR instruments follows: 95°C for 5 minutes; followed by 45 cycles of 95°C for 30 s, 56°C for 30 s, this condition was used for all primer pairs and 72°C for 30 s with a final heating at 72°C for 10 minutes. Amplicons were analyzed by 1% agarose. DNA marker (1kb Ladder Invitrogen) for confirm the size of band is correct, gel-electrophoresis containing ethidium bromide and photographed under UV illumination. Gel-purified amplicons (using Min Elute Purification Kit, Qiagen) were sequenced using 3130 Genetic Analyser (Applied Biosystems). Sequences were aligned results using GENETIYX Wyn Version 9 (Edit View 5 NT Software). The results of sequencing nucleotides compared with NCBI databases using BLAST program shows *pfatpase6* gene of *Plasmodium falciparum* 2300 strain. It was nucleotides homologous 2750 base pair of 99% with isolates sequence ID (KC 577098.1; JN 983273.1; AB 576310.1; AL 844501.1; XM0013509581) which is *Plasmodium falciparum* Serca gene (sarcoplasmic reticulum endoplasmic ATPase6 Ca<sup>2+</sup>)

## 3. Results



**Figure 1:** The results of PCR *pfatpase6 Plasmodium falciparum* gene strain 2300 in the control group and the treatment group with artemisinin exposure of  $IC_{50}$  concentration using 5 pairs of primers. Description A: Control, B: PO1, C: PO2, D: PO3, E: PO4, M:Marker, 1FR: Primer 1 Forward-Reverse, 2FR: Primer 2 Forward-Reverse, 4FR: Primer 4 Forward Reverse, 5FR: Primer 5 Forward-Reverse, 6FR: Primer 6 Forward-Reverse, a: 737 bp, b: 813 bp, c:700 bp, d: 550 bp, e: 876 bp.

### 3.1. Artemisinin exposure on *Plasmodium falciparum* 2300 $IC_{50}$ values

$IC_{50}$  values on first artemisinin exposure (PO1)  $5 \times 10^{-8} M$ , second artemisinin exposure (PO2)  $7.5 \times 10^{-7} M$ , third artemisinin exposure (PO3)  $2.5 \times 10^{-5} M$  and fourth artemisinin exposure (PO4)  $5 \times 10^{-4} M$ . Repeated artemisinin exposure influence changes in  $IC_{50}$  [22].

### 3.2. Artemisinin exposure on *Plasmodium falciparum* 2300 *pfatpase6* sequence

Following exposure to artemisinin, five regions in *Plasmodium falciparum* 2300 *pfatpase6* exons 1 and 2 were PCR amplified and sequenced. These regions contained codons of 10 *pfatpase6* amino acids, namely, I89, L263, E431, N460, N465, A623, N683, S769, I898, and C1031, commonly mutated in artemisinin-resistant *Plasmodium falciparum*. As expected, amplicon sizes remained unchanged from artemisinin-untreated control, despite increase in  $IC_{50}$  values (Fig 1).

Sequencing of the five amplicons from each of the four artemisinin-exposed *Plasmodium falciparum* 2300 lines revealed no changes among these 10 *pfatpase6* amino acids from control, although there were a number of sporadic silent mutations present in some of the artemisinin-exposed lines. Experimental model point mutations in *Plasmodium falciparum pfatpase6* gene exposed with recurring artemisinin showed a similarity to nucleotide region changes (PO1, PO2, PO3 and PO4). Transition point mutations in exon 1 nucleotide region 123 changes nucleotide base T - C, at exon 2 on the nucleotide region 2035 the nucleotide bases changes G - A, nucleotide region 2148 changing bases C - T. Transversion point mutations occur in exon 2 nucleotide region 1915 and 2138 changing bases A - T (Figure 2).

#### 4. Discussion

The results of complete DNA sequencing for *pfatpase6* gene references 4.049 base pairs (bp) located on chromosome1. The *pfatpase6* gene contains three exons and two introns. Fragments start to 1793 base pairs as the coding region of exon 1, exon 2 until 3498 base pair fragments and the remaining fragments up to 4.049 base pairs as exons 3. The sequencing results of isolates of *Plasmodium falciparum* strain 2300. The region codon 69, 263, 431, 460, 465, 623, 683, 769.898, 1031, where common mutation always occur, was associated with *Plasmodium* resistant to artemisinin.

The results of the sequencing alignment analysis of the nucleotide sequence of the gene *pfatpase6 Plasmodium Falciparum* of strains 2300, the control treatment group (C) and the artemisinin repeated exposure treatment group (PO1, PO2, PO3 and PO4) showed that the control group did not show any visible mutations in the arrangement of nucleotide bases. The artemisinin repeated exposure treatment group on PO1, PO2, PO3 and PO4 showed a point mutation because of there placement of one pair of nucleotide bases that vary in length and nucleotide bases ranging from exon1 to exon 2 at *pfatpase6* genes. Point mutations were in the form of transition and transversion.

Variation in the arrangement of nucleotides in the treatment group of repeated exposure to artemisinin occur in *Plasmodium falciparum* of strain 2300 (PO1, PO2, PO3 and PO4). The results of this study indicate the existence of genetic diversity in exon 1 and exon 2 *pfatpase6* gene. The genetic diversity of *Plasmodium falciparum* generate mutants with variation pattern of mutations in the diverse variable region. The same point mutation on PO1, PO2, PO3 and PO4 nucleotide region 123, 2035, 2043, 2138 and 2148 results from this study indicate that region of the nucleotide bases can be used as a marker of *Plasmodium falciparum* resistant to artemisinin marked




KONTROL 2300 PAPUA (Final)	1	AAGAAAGAGTATTTTGAATTGATATAAATCAATTTAATGATTATTAATAAAATATATAGTAGCTGCATTGAT	80
P01- 2300 PAPUA (Final)	1	.....	80
P02- 2300 PAPUA (Final)	1	.....	80
P03-2300-PAPUA (Final)	1	.....	80
P04- 2300 PAPUA (Final)	1	.....	80
KONTROL 2300 PAPUA (Final)	81	FAGTTT CGTGTAACTTTATTAGATAGAAACATAAAAJAAATGAAATATGTGATTTTATTGACCATTAGTTATAGTAT	160
P01- 2300 PAPUA (Final)	81	.....	160
P02- 2300 PAPUA (Final)	81	.....	160
P03-2300-PAPUA (Final)	81	.....	160
P04- 2300 PAPUA (Final)	81	.....	160
KONTROL 2300 PAPUA (Final)	161	TATATTAATATTAAATGCTGCCGTGGTGTATGGGAAATGTAATGCTGAAAAATCITTAGAAGCTTTAAAAAGAAATTA	240
P01- 2300 PAPUA (Final)	161	.....	240
P02- 2300 PAPUA (Final)	161	.....	240
P03-2300-PAPUA (Final)	161	.....	240
P04- 2300 PAPUA (Final)	161	.....	240
KONTROL 2300 PAPUA (Final)	241	CAACCTACCAAAGCTAAAGTATTACGAGATGGGAAGTGGGAATATTGATAGTAAATATTATTGTTGGTATATTAT	320
P01- 2300 PAPUA (Final)	241	.....	320
P02- 2300 PAPUA (Final)	241	.....	320
P03-2300-PAPUA (Final)	241	.....	320
P04- 2300 PAPUA (Final)	241	.....	320
KONTROL 2300 PAPUA (Final)	321	TGAATTGAGTGTGGTAAATAAATCCCGCTGATGCAAGATTAATTAATAATATTCAACAAGTTTAAAAAGTTGAAACAG	399
P01- 2300 PAPUA (Final)	321	.....	400
P02- 2300 PAPUA (Final)	321	.....	399
P03-2300-PAPUA (Final)	321	.....	399
P04- 2300 PAPUA (Final)	321	.....	399
KONTROL 2300 PAPUA (Final)	400	AGTATGTTAAACAGGAATCCTGTTCAAGTACCAATATGCTGAAAAATGGAAGATAGTTAAAAAATTGTGAATACA	479
P01- 2300 PAPUA (Final)	401	.....	480
P02- 2300 PAPUA (Final)	400	.....	479
P03-2300-PAPUA (Final)	400	.....	479
P04- 2300 PAPUA (Final)	400	.....	479
KONTROL 2300 PAPUA (Final)	480	GTTGAAAAAATATTATTATTATCTACCCTATTTGATGTGGTATGATGATAGCTTTGTAATCAACATGGTATGA	559
P01- 2300 PAPUA (Final)	481	.....	560
P02- 2300 PAPUA (Final)	480	.....	559
P03-2300-PAPUA (Final)	480	.....	559
P04- 2300 PAPUA (Final)	480	.....	559
KONTROL 2300 PAPUA (Final)	560	AAGCTGAAATAAGTCAATTTCAAGATGCTGTATAGAAATCAATAATGAAAGATACTGAAACAGCTTACAAATAAATAATC	639
P01- 2300 PAPUA (Final)	561	.....	640
P02- 2300 PAPUA (Final)	560	.....	639
P03-2300-PAPUA (Final)	560	.....	639
P04- 2300 PAPUA (Final)	560	.....	639
KONTROL 2300 PAPUA (Final)	640	GATTTATTTGATCAAGAAATATCAAAATGATTTTGTAAATATGTGTAATGATGTAATGATTAATTTAAAGATTTGTC	719
P01- 2300 PAPUA (Final)	641	.....	720
P02- 2300 PAPUA (Final)	640	.....	719
P03-2300-PAPUA (Final)	640	.....	719
P04- 2300 PAPUA (Final)	640	.....	719
KONTROL 2300 PAPUA (Final)	720	AGATGCAATGATGGTTCATTTTATATAGGTTGTTTAAATATTTTAAATTAATGTTGCTTTAGCTGTTGCTGCTAAG	799
P01- 2300 PAPUA (Final)	721	.....	800
P02- 2300 PAPUA (Final)	720	.....	799
P03-2300-PAPUA (Final)	720	.....	799
P04- 2300 PAPUA (Final)	720	.....	799
KONTROL 2300 PAPUA (Final)	800	CAGAAAGATTGCCAGAGTCAAAACACTGTTTAGCTTTAAGAAAGAAAGATGATGTAATAAATAAATAATGCTATAGTAAGA	879
P01- 2300 PAPUA (Final)	801	.....	880
P02- 2300 PAPUA (Final)	800	.....	879
P03-2300-PAPUA (Final)	800	.....	879
P04- 2300 PAPUA (Final)	800	.....	879
KONTROL 2300 PAPUA (Final)	880	AAATTAAGAAAGTGTGAGACGTTAGATGTAAGACGTTATATGTTGATTAATAAGGTTAGCCCTTAGAAAGAAAT	959
P01- 2300 PAPUA (Final)	881	.....	960
P02- 2300 PAPUA (Final)	880	.....	959
P03-2300-PAPUA (Final)	880	.....	959
P04- 2300 PAPUA (Final)	880	.....	959
KONTROL 2300 PAPUA (Final)	960	GAGAACAAAGCTGTTTTCATTTGTTTAGAAATGTTGTTTAAAGATAAGAACTATGTAATAAATAAATAATGATAGCTATT	1039
P01- 2300 PAPUA (Final)	961	.....	1040
P02- 2300 PAPUA (Final)	960	.....	1039
P03-2300-PAPUA (Final)	960	.....	1039
P04- 2300 PAPUA (Final)	960	.....	1039

with an increase  $IC_{50}$  value of artemisinin, which implies a decline in the sensitivity of

KONTROL 2300 PAPUA (Final)	1040	.....A CTTT ATGGAAGTTCAAAGTAAAGAAATGATATATATGGAGGTGAATGTCCTTTTAAATAAAATAAAGATGAAAGGA	1119
P01 - 2300 PAPUA (Final)	1041	.....	1120
P02 - 2300 PAPUA (Final)	1041	.....	1114
P03 - 2300 PAPUA (Final)	1040	.....	1119
P04 - 2300 PAPUA (Final)	1040	.....	1115
KONTROL 2300 PAPUA (Final)	1120	.....AATGTGGAAGCTTTAAAGGATGATGGAGGAAGGATCAATTGATGAAGCTGATCCATATAGTGAATTTTCTAGTGA	1199
P01 - 2300 PAPUA (Final)	1121	.....	1200
P02 - 2300 PAPUA (Final)	1120	.....	1199
P03 - 2300 PAPUA (Final)	1120	.....	1199
P04 - 2300 PAPUA (Final)	1120	.....	1199
KONTROL 2300 PAPUA (Final)	1200	.....AAGTAAGAATGAAAAATGATTAAGCAACCAATAATTAATATAATAGTAAGAGAGTGTAAAAATTAAGAAATAAATTAATATA	1279
P01 - 2300 PAPUA (Final)	1201	.....	1280
P02 - 2300 PAPUA (Final)	1200	.....	1279
P03 - 2300 PAPUA (Final)	1200	.....	1279
P04 - 2300 PAPUA (Final)	1200	.....	1279
KONTROL 2300 PAPUA (Final)	1280	.....TTGCTTAAGAAGAAATGAAATGAAATGAAATGCAATATTAAGTAGAGGTTAAAAATTAAGAAATTAATTAATATA	1359
P01 - 2300 PAPUA (Final)	1281	.....	1360
P02 - 2300 PAPUA (Final)	1280	.....	1359
P03 - 2300 PAPUA (Final)	1280	.....	1359
P04 - 2300 PAPUA (Final)	1280	.....	1355
KONTROL 2300 PAPUA (Final)	1360	.....AATTGTATTCAGAAATGATATATAATTTTAAATATGTTTAAATATGAAATGAAATGAAATGAAATTTCTGTATTCAGAA	1439
P01 - 2300 PAPUA (Final)	1361	.....	1440
P02 - 2300 PAPUA (Final)	1360	.....	1439
P03 - 2300 PAPUA (Final)	1360	.....	1439
P04 - 2300 PAPUA (Final)	1360	.....	1439
KONTROL 2300 PAPUA (Final)	1440	.....AAGTGAATAGTAAAAAATTTGGAGAGAGTACCGAATTAAGCTTTATAGTTTGTATGATAAATTGATATATTACGAA	1519
P01 - 2300 PAPUA (Final)	1441	.....	1520
P02 - 2300 PAPUA (Final)	1440	.....	1519
P03 - 2300 PAPUA (Final)	1440	.....	1519
P04 - 2300 PAPUA (Final)	1440	.....	1519
KONTROL 2300 PAPUA (Final)	1520	.....AATTGTATTCAGAAATGATATATAATTTTAAATATGTTTAAATATGAAATGAAATGAAATTTCTGTATTCAGAA	1599
P01 - 2300 PAPUA (Final)	1521	.....	1600
P02 - 2300 PAPUA (Final)	1520	.....	1599
P03 - 2300 PAPUA (Final)	1520	.....	1599
P04 - 2300 PAPUA (Final)	1520	.....	1595
KONTROL 2300 PAPUA (Final)	1600	.....TACCAAGGGGTATGAAAGAAATTTCTTAGTTCAAAAAATGATAACAATGATATTACAGTACATTGAATGAAATGATA	1679
P01 - 2300 PAPUA (Final)	1601	.....	1680
P02 - 2300 PAPUA (Final)	1600	.....	1679
P03 - 2300 PAPUA (Final)	1600	.....	1679
P04 - 2300 PAPUA (Final)	1600	.....	1679
KONTROL 2300 PAPUA (Final)	1680	.....GAATTTAAAGAAATGCTAACCAATTCTAATTACTACAGCTCAGGCAACAAGAAATGATATGAAGCTATAAGAGAAATA	1759
P01 - 2300 PAPUA (Final)	1681	.....	1760
P02 - 2300 PAPUA (Final)	1680	.....	1759
P03 - 2300 PAPUA (Final)	1680	.....	1759
P04 - 2300 PAPUA (Final)	1680	.....	1759
KONTROL 2300 PAPUA (Final)	1760	.....CATTGAGCATGGCAACAATTGAAATTTGTTCCACTCAAAATGGGTAATAAATAAATACCAATCAACCAATATA	1839
P01 - 2300 PAPUA (Final)	1761	.....	1840
P02 - 2300 PAPUA (Final)	1760	.....	1839
P03 - 2300 PAPUA (Final)	1760	.....	1839
P04 - 2300 PAPUA (Final)	1760	.....	1839
KONTROL 2300 PAPUA (Final)	1840	.....AATAATAACAAAGAAATAAATAAATAATAATAATAATAATAATAATAATAATAATAATAATAATAATAATAATAATAATA	1919
P01 - 2300 PAPUA (Final)	1841	.....	1920
P02 - 2300 PAPUA (Final)	1840	.....	1919
P03 - 2300 PAPUA (Final)	1840	.....	1919
P04 - 2300 PAPUA (Final)	1840	.....	1919
KONTROL 2300 PAPUA (Final)	1920	.....AAAAATATTGAATTCACTAGAGAAAGGAACTTATGAGTGTATTTGTTGAAAATAAAAAAAAAGAAATAATATTGAT	1999
P01 - 2300 PAPUA (Final)	1921	.....	2000
P02 - 2300 PAPUA (Final)	1920	.....	1999
P03 - 2300 PAPUA (Final)	1920	.....	1999
P04 - 2300 PAPUA (Final)	1920	.....	1999
KONTROL 2300 PAPUA (Final)	2000	.....GTAAAGGTGCACTGAGATAATAAAAAATTTGATATTAATTAACGAAAAATGATATACGTCATTAAATGAAACT	2079
P01 - 2300 PAPUA (Final)	2001	.....	2080
P02 - 2300 PAPUA (Final)	2000	.....	2079
P03 - 2300 PAPUA (Final)	2000	.....	2079
P04 - 2300 PAPUA (Final)	2000	.....	2079
KONTROL 2300 PAPUA (Final)	2080	.....TAAAAAATGAATTCATAATAAGATTCAAAATATGGAAGAAAGGATTAAGAACATTAAGCTTTGCTATAAAAAAT	2159
P01 - 2300 PAPUA (Final)	2081	.....	2160
P02 - 2300 PAPUA (Final)	2080	.....	2159
P03 - 2300 PAPUA (Final)	2080	.....	2159
P04 - 2300 PAPUA (Final)	2080	.....	2159

*Plasmodium falciparum* strains 2300 against artemisinin as indicated by the increase in





**Figure 2:** Multi Alignment of *Plasmodium falciparum pftpase6* genes strains 2300 in the control group and the artemisinin repeated exposure treatment group with  $IC_{50}$  concentrations Note: similarity to nucleotide region changes.

the value of  $IC_{50}$  artemisinin, causing extra-time clearance parasites in the body and the speed of which can cause a recurrence of severe malaria until death [22]. This is in accordance with research conducted by Afoakwah *et al.* 2011 [23]. 2652 samples collected from 35 countries conducted from 1990 - 2009 (25 Sub-Saharan Africa, 5 Asia, 3 Americans and 2 Oceania), which found 44 SNPs in *pftpase6* genes with a mutation in some codons variations. The prevalence of these SNPs was associated with decreased sensitivity of *Plasmodium falciparum* to artemisinin. Polymorphism in 87 isolates of *Plasmodium falciparum* from Niger also found 6 SNPs in the codon of D537D *pftpase6* gene, namely, K561N, N569K, A630S, G639D, K716R, which were used to test the efficacy of artemisinin monitoring [24].

Analysis of genetic diversity of *pftpase6* of 862 isolates of *Plasmodium falciparum* in 19 populations from Asia, Africa, South America and Oceania were 71 SNPs identified in the 106 *nucleotide haplotypes* with a specific mutation on every continent, and the frequency was below 5%. The discovery of SNPs is high enough on the isolates of *Plasmodium*, after molecular evolution analysis results did not find significant changes

in *pfatpase6* gene in all populations, so that the *pfatpase6* gene is still appropriate as a marker for monitoring artemisinin resistance against *Plasmodium falciparum* [25].

Mutations in amino acids may alter the conformity of the drug binding site and could potentially lead to decreased sensitivity to artemisinin. The *pfatpase6* gene is the target of artemisinin in compounds in *Plasmodium falciparum*. There was a relationship between the *pfatpase6* S769N substitution and improvement of artemether in vitro  $IC_{50}$  values in isolates from French Guiana 769 residue located in the *N cytoplasmic* domain (nucleotide binding) that is close to the important conserved area are needed for the development of the ATPase cycle, the bond and the release of calcium that can affect the S769N mutation in a conformational change [8].

In the transgenic parasites laboratory, the changes in artemisinin sensitivity are associated with mutations in relatively small L263E about 10-20% which gives impact on  $IC_{50}$  values change, but the change in  $IC_{50}$  values sufferers field isolates originating from western Cambodia, Pailin (2.3 nM) showed a decrease in parasite clearance time compared to sufferers of WanhPha, Thailand (1.5 nM). What was found there was a single amino acid mutation of L363E on *pfatpase6*. These results demonstrate that the role of variability in the gene cannot be controlled similar to parasites transgenic laboratory, so that  $IC_{50}$  values have very important clinical implications for assessing drug resistance. This shows that *pfatpase6* is a potential target for artemisinin due to changes in the value of  $IC_{50}$  artemisinin against parasites associated with amino acid changes, which were based on the model of the structure and the drug binding sites on the receptor, so that mutations in *pfatpase6* would affect the expression of the phenotype [26].

The test of In vitro sensitivity of *dihydro artemisinin* on *Plasmodium falciparum* isolates collected from Cameroon started 2002-2006 showed that a single mutation was found in the E431K *pfatpase6* gene as a warning signal to perform continuous monitoring on molecular markers and the activity of artemisinin and its derivatives in vitro [27].

Mutations of I89T, A438D, N464, N465S, N465, E847K, in the *pfatpase6* gene samples from Pailin (Cambodia West) and mutations in the *pfatpase6* gene of I89T, H243Y, L263E, A438D, N465S samples of WangPha (Thailand) showed that there is no clear pattern in the gene that causes resistance to artemisinin [21].

On the *Pfatpase6* gene mutation found in isolates of *Plasmodium falciparum* isolates from Vietnam with 8 mutations (four non synonymous I89T, N463S, N465S and N683K), three synonymous (N460N, I898I and C1031C) and one double deletions (<sup>^</sup>463-464), there was no discovery of mutations S769N or A623E, E431K, but the mutation of N683K were found in Cambodia that may be specific for *Plasmodium*

*falciparum* from Southeast Asia. The presence of mutations N460N, N463S, N465S and N683K and double deletions ( $\Delta$  463-464) led to the widening of the location of the nine asparagines in interspecies variable region of *pfatpase6* (domain-specific) for *Plasmodium* species, so that these modification scan alter the adjustment of *Plasmodium* that can affect sensitivity to artemisinin [28].

The same study conducted on clinical isolates in Senegal found that the combination of two mutations E431K and A623E are indicating an increase in the IC<sub>50</sub> value, so that a point mutation can be used for molecular monitoring of artemisinin derivatives in vitro continuous surveillance [8]. Artemisinin repeated exposure can cause in the form of point mutations in the genes of transition and transversion of *pfatpase6* genes in *Plasmodium falciparum* strains 2300 in vitro. Change of bases at the same nucleotide region on experiment model *Plasmodium falciparum* exposed recurring artemisinin in vitro can be used as a marker of Plasmodium resistant to artemisinin. Conclusion of this research artemisinin repeated exposure can cause point mutations in *pfatpase6* genes *Plasmodium falciparum* of strains 2300 in vitro.

## Acknowledgements

The authors thank the Directorate General of Higher Education (*Dirjen Dikti*), Ministry of Education and Culture, Republic of Indonesia for BPPS doctoral program 2009, Faculty of Medicine, Airlangga University.

## References

- [1] World Health Organization. 2010. Global report on antimalarial drug efficacy and drug resistance 2000-2010. Geneva. 32
- [2] Veiga MI, Ferreira PE, Schmidt BA, Schmidt BA, Ribacke U, Bjorkman A, Tichopad A, Gil JP. Antimalarial exposure delays *Plasmodium falciparum* intra erythrocytic cycle and drives drug transporter Genes expression. Plos One.2010; 5 (8): e12408.
- [3] Ullastres A, Merenciano M, Guro IU, Gonzales J. 2016. Stress and environmental regulation of gene expression and adaptation in bacteria: Transposable elements: a toolkit for stress and environmental adaptation in bacteria. John Willey & Sons Inc.Newjwersy. Vol 1. Chapter 2.10.137-140.
- [4] Bla B.K, Yavo W, Trebissou J, Kipre R.G, Yapi F.H, N'guessan J.N. Djaman J.A. 2014. Polymorphisms of the *Pfatpase6* and *Pfcrf* gene and their relationship with the *in vitro* susceptibility to dihydroartemisinin and chloroquine of *Plasmodiumfalciparum*

- isolates from Abobo, Côte d'Ivoire. *Annals Parasitology*.60(40):259-266.
- [5] Globler L, Chavchich M, Haynes R.K, Edstein M.D, Grobler A. 2014. Assessment of the induction of dormant ring stages in *Plasmodium falciparum* parasites by artemisone and artemisone entrapped in pheroïd vesicles in vitro. *Antimicrobial Agents and Chemotherapy*. 58 (12): 7579-7582
- [6] Isozumi R, Uemura H, Kimata I, Ichinose Y, Logedi J, Omar A.H, Kaneko A. 2015. Novel mutations in K13 propeller gene of artemisinin-resistant *Plasmodium falciparum*. *Emerging Infectious Diseases*. 21 (3):
- [7] Mugittu K, Genton B, Mshinda H and Beck HP. Molecular monitoring of *Plasmodium falciparum* resistance to artemisinin in Tanzania. *Malaria Journal*. 2006; 5:126
- [8] Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau Pujijalon O. Resistance of *P.falciparum* field isolates to In vitro artemether and point mutations of the SERCA type Pf ATPase6. *The Lancet*. 2005; 366:1960-1963
- [9] Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S. Mefloquine resistance in *Plasmodium falciparum* and increased *pfmdr1* gene copy number. *The Lancet*. 2004; 364: 438-447
- [10] Ferreira ID, Lopes D, Martenelli A, Ferreira C, Rosario VE, Cravo P. In vitro assessment of artesunate, artemether and amodiaquine susceptibility and molecular analysis of putative resistance associated mutation of *Plasmodium falciparum* from Sao Tome and Principe. *Tropical Medicine and International*. 2007; 12: 353-362
- [11] Dahlstrom S, Veiga MI, Ferreira P, Martensson A, Kaneko A, Anderson B, Bjorkman A, Gil JP. Diversity of the sarco/endoplasmic reticulum Ca(2+) ATPase6 orthologue of *Plasmodium falciparum* (PfATP6). *Infect Genet Evol*. 2008; 8:340-345
- [12] Zakary S, Hemati Sz, Pirahmadi S, Afsharpad M, Raeisi A and Djadid ND. Molecular assessment of atpase6 mutations associated with artemisinin resistance among unexposed and exposed *Plasmodium falciparum* clinical isolates to artemisinin-based combination therapy *Malaria Journal* 2012, 11:37
- [13] Wilairat P, Kumpornsinn K, Chookajorn T. 2016. *Plasmodium falciparum* malaria: Convergent evolutionary trajectories towards delayed clearance following artemisinin treatment. *Medical Hypotheses* 90:19-22
- [14] Paloque L, Ramadani A.P, Mercereau-Pujijalon O, Augereau J.M, Benoit-Vical F. 2016. *Plasmodium falciparum*: multi faceted resistance to artemisinins. *Malar J* 15:149
- [15] Njokah M.J, Kang J.N, Kinyua J, Kariuki D, Kimani F.T. 2016. In vitro selection of *Plasmodium falciparum* *Pfcr* and *Pfmdr1* variants by artemisinin. *Malar J* . 15:381.



- [16] Trager W and Jensen J.B. Human malaria parasites in continuous culture. *Science* 1976; 193: 673-675
- [17] Yuan L, Hao M, Wu L, Zhao Z, Rosental B.M, Li X, He Y, Sun L, Feng G, Xiang Z, Cui L and Yang Z. 2014 Refrigeration provides a simple means to synchronize in vitro cultures of *Plasmodium falciparum*. *Exp Parasitol*. 140: 18-23. doi:10.1016/j.exppara.2014.03.010.
- [18] Garcia, L. Determination of parasitemia: Diagnostic medical parasitology 2007; ed. 5. ASM Press.Washington DC.
- [19] Ljungstrom I, Perlmann H, Schlictherle M, Scherf A, Wahlgren M. *Methods in Malaria Research*.2004; Ed 4. 1-240
- [20] Sanz LM, Crespo B, De-cozar C, Ding XC, Liengo JL, Burrows JN, Garcia -Butos JF, Gamo FJ. *P.falciparum* in vitro killing rates allow to discriminate between different antimalarial mode of action. *Plos One*. 2012; 7(2): e30949
- [21] Imwong M, Dondorpn AM, Nosten F, Yi P, *et al*. Exploring the contribution of candidate genes to artemisinin resistance in *P.falciparum*. *Antimicrobial Agents and Chemotherapy*. 2010; 54 (7): 2886-2892
- [22] Maslachah L, Dachlan Y.P, Nidom C.A, Fitri L.E. 2015. Phenotypic Profile of *Plasmodium falciparum* Papua 2300 strain Exposed to in vitro Antimalaria Artemisinin. *MKB*. 47(1).1-9.
- [23] Afoakwah R, Boampong JN, Acheampong DO, and Nwaefuna EK. Polymorphisms in *Plasmodium falciparum* adenosine triphosphatase6 (*pfatpase6*) gene and their significance in finding the genetic marker for artemisinin resistance. *European Journal of Experimental Biology*. 2011; 1(3): 7-13
- [24] Ibrahim ML, Khim N, Adam HH, Arie F, Duchemin JB. Polymorphism of *pfatpase 6* in Niger: detection of three new point mutation. *Malaria Journal*.2008; 8(28): 1-4
- [25] Miao M, Wang Z, Yang Z, Yuan L, Parker D.M, Putaporntip C, Jongwutiwes S, Xangsayarath P, Pongvongsa T, *et al*. Genetic diversity and lack of artemisinin selection signature on the *Plasmodium falciparum* ATP in greater Mekong Subregion. *Plos One*.2013; 8 (3):e59192
- [26] Valderramos A..G, Fidock D..A. Transporters involved in resistance to antimalarial drugs. *Trend in Pharmacological Science*. 2006; 27(11): 594-601
- [27] Tahar R, Ringwald P, Basco LK. Molecular Epidemiology of malaria in Camerroun XXVIII in vitro activity of dihydroartemisinin against clinical isolates of *Plasmodium falciparum* and sequence analysis of the *P.falciparum*ATPase6 Gene. *Am.J.Trop Med.Hyg*.2009; 81 (1): 13-18

- [28] Bertaux L, Quang LH, Sinou V, Thanh NX, Parzy D. New PfATPase6 mutation found in *Plasmodium falciparum* isolates from Vietnam. *Antimicrobial Agent and Chemotherapy*.2009; 53 (10): 4570-4571